BioAtla Inc (BCAB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 94/100 (CRITICAL), 0.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.46% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- BioAtla Announces Share Consolidation
- BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
- Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
- BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
- BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
- BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
- BioAtla (BCAB) Q3 2025 Earnings Call Transcript
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for BioAtla Inc.
Full BCAB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.